Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 94

1.

Panitumumab.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

2.

Panitumumab in the treatment of metastatic colorectal cancer, including wild-type RAS, KRAS and NRAS mCRC.

McGregor M, Price TJ.

Future Oncol. 2018 Oct;14(24):2437-2459. doi: 10.2217/fon-2017-0711. Epub 2018 May 8.

PMID:
29737864
3.

Review on comparative efficacy of bevacizumab, panitumumab and cetuximab antibody therapy with combination of FOLFOX-4 in KRAS-mutated colorectal cancer patients.

Pathak S, S S, Banerjee A, Marotta F, Gopinath M, Murugesan R, Zhang H, B B, Girigoswami A, Sollano J, Sun XF.

Oncotarget. 2017 Nov 16;9(7):7739-7748. doi: 10.18632/oncotarget.22471. eCollection 2018 Jan 26. Review.

4.

Different Toxicity of Cetuximab and Panitumumab in Metastatic Colorectal Cancer Treatment: A Systematic Review and Meta-Analysis.

Petrelli F, Ardito R, Ghidini A, Zaniboni A, Ghidini M, Barni S, Tomasello G.

Oncology. 2018;94(4):191-199. doi: 10.1159/000486338. Epub 2018 Jan 23. Review.

PMID:
29393280
5.

Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review.

Han van Krieken J, Kafatos G, Bennett J, Mineur L, Tomášek J, Rouleau E, Fabian P, De Maglio G, García-Alfonso P, Aprile G, Parkar P, Downey G, Demonty G, Trojan J.

BMC Cancer. 2017 Nov 28;17(1):798. doi: 10.1186/s12885-017-3740-4. Review.

6.

Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer.

Ketzer S, Schimmel K, Koopman M, Guchelaar HJ.

Clin Pharmacokinet. 2018 Apr;57(4):455-473. doi: 10.1007/s40262-017-0590-9. Review.

7.

Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives.

Battaglin F, Dadduzio V, Bergamo F, Manai C, Schirripa M, Lonardi S, Zagonel V, Loupakis F.

Expert Opin Biol Ther. 2017 Oct;17(10):1297-1308. doi: 10.1080/14712598.2017.1356815. Epub 2017 Jul 28. Review.

PMID:
28752777
8.

The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.

Huxley N, Crathorne L, Varley-Campbell J, Tikhonova I, Snowsill T, Briscoe S, Peters J, Bond M, Napier M, Hoyle M.

Health Technol Assess. 2017 Jun;21(38):1-294. doi: 10.3310/hta21380. Review.

9.

Patient considerations in metastatic colorectal cancer - role of panitumumab.

Rogers JE.

Onco Targets Ther. 2017 Apr 7;10:2033-2044. doi: 10.2147/OTT.S115430. eCollection 2017. Review.

10.
11.

Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma: A Randomized Clinical Trial.

Siu LL, Waldron JN, Chen BE, Winquist E, Wright JR, Nabid A, Hay JH, Ringash J, Liu G, Johnson A, Shenouda G, Chasen M, Pearce A, Butler JB, Breen S, Chen EX, FitzGerald TJ, Childs TJ, Montenegro A, O'Sullivan B, Parulekar WR.

JAMA Oncol. 2016 Dec 8. doi: 10.1001/jamaoncol.2016.4510. [Epub ahead of print]

PMID:
27930762
12.

Systematic review and meta-analysis of the risk of severe and life-threatening thromboembolism in cancer patients receiving anti-EGFR monoclonal antibodies (cetuximab or panitumumab).

Miroddi M, Sterrantino C, Simmonds M, Caridi L, Calapai G, Phillips RS, Stewart LA.

Int J Cancer. 2016 Nov 15;139(10):2370-80. doi: 10.1002/ijc.30280. Epub 2016 Jul 28. Review.

13.

Phase II trial of panitumumab with irinotecan as salvage therapy for patients with advanced or recurrent colorectal cancer (TOPIC study).

Nishi T, Hamamoto Y, Nagase M, Denda T, Yamaguchi K, Amagai K, Miyata Y, Yamanaka Y, Yanai K, Ishikawa T, Kuroki Y, Fujii H.

Oncol Lett. 2016 Jun;11(6):4049-4054. Epub 2016 May 6.

14.

Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.

Tebbutt NC, Price TJ, Ferraro DA, Wong N, Veillard AS, Hall M, Sjoquist KM, Pavlakis N, Strickland A, Varma SC, Cooray P, Young R, Underhill C, Shannon JA, Ganju V, Gebski V.

Br J Cancer. 2016 Mar 1;114(5):505-9. doi: 10.1038/bjc.2015.440. Epub 2016 Feb 11.

15.

[A Case of Thrombotic Thrombocytopenic Purpura in a Patient Undergoing FOLFOX6 plus Panitumumab Therapy for Unresectable Recurrent Rectal Cancer with a Rapidly Progressive Course].

Kato K, Michishita Y, Oyama K, Hatano Y, Nozawa T, Ishibashi M, Konda R, Sasaki A.

Gan To Kagaku Ryoho. 2016 Jan;43(1):133-6. Japanese.

PMID:
26809542
16.

Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer.

Patel SB, Gill D, Garrido-Laguna I.

Onco Targets Ther. 2015 Dec 30;9:75-86. doi: 10.2147/OTT.S68558. eCollection 2016. Review.

17.
18.

Pharmacokinetic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancer.

Lo L, Patel D, Townsend AR, Price TJ.

Expert Opin Drug Metab Toxicol. 2015;11(12):1907-24. doi: 10.1517/17425255.2015.1112787. Epub 2015 Nov 16. Review.

PMID:
26572750
19.

Prophylactic Effect of Oral Minocycline in Combination with Topical Steroid and Skin Care Against Panitumumab-induced Acneiform Rash in Metastatic Colorectal Cancer Patients.

Yamada M, Iihara H, Fujii H, Ishihara M, Matsuhashi N, Takahashi T, Yoshida K, Itoh Y.

Anticancer Res. 2015 Nov;35(11):6175-81.

PMID:
26504047
20.

Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review.

Trojan J, Mineur L, Tomášek J, Rouleau E, Fabian P, de Maglio G, García-Alfonso P, Aprile G, Taylor A, Kafatos G, Downey G, Terwey JH, van Krieken JH.

PLoS One. 2015 Oct 22;10(10):e0140717. doi: 10.1371/journal.pone.0140717. eCollection 2015.

Supplemental Content

Loading ...
Support Center